RxDoctor Payments Data

Jillian Sonkin

Family · Lynbrook, NYNPI 1639473267

Payments from drug & device makers

$9,621in general payments, 2019–2025

Across 466 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$915
  • AbbVie$842
  • Lilly USA, LLC$746
  • AstraZeneca$658
  • Pfizer$621
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,610100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,621 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$93,943
Medicare patients
288
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$40,462
MounjaroTirzepatide26$33,431
FarxigaDapagliflozin Propanediol25$28,221
TrulicityDulaglutide11$28,004
Xigduo XrDapaglifloz Propaned/Metformin11$15,488
Tresiba Flextouch U-200Insulin Degludec17$15,336
JanuviaSitagliptin Phosphate13$14,751
EliquisApixaban12$12,461
Breo ElliptaFluticasone/Vilanterol20$9,332
SymbicortBudesonide/Formoterol Fumarate13$4,229
Metoprolol Succinate111$1,617
Rosuvastatin Calcium111$1,530
Atorvastatin Calcium162$1,346
SynthroidLevothyroxine Sodium33$1,304
Levothyroxine Sodium71$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$746$61,43437 claims
Novo NordiskOzempic$1,862$40,46227 claims
AstraZenecaFarxiga, Symbicort$658$32,45138 claims
MerckJanuvia$291$14,75113 claims
PfizerEliquis$621$12,46112 claims
GSKBreo Ellipta$519$9,33220 claims
AbbVieSynthroid$842$1,30433 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$99$1,11471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Lynbrook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →